CLINICAL TRIALS PROFILE FOR CORTIFOAM

All Clinical Trials for CORTIFOAM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002855 ↗	Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1996-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00002855 ↗	Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer	Completed	M.D. Anderson Cancer Center	Phase 3	1996-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.

Clinical Trial Conditions for CORTIFOAM

Condition Name

Condition Name for CORTIFOAM
Intervention	Trials
Prostate Cancer	1

Condition MeSH

Condition MeSH for CORTIFOAM
Intervention	Trials
Prostatic Neoplasms	1

Clinical Trial Locations for CORTIFOAM

Trials by Country

Trials by Country for CORTIFOAM
Location	Trials
United States	1

Trials by US State

Trials by US State for CORTIFOAM
Location	Trials
Texas	1

Clinical Trial Progress for CORTIFOAM

Clinical Trial Phase

Clinical Trial Phase for CORTIFOAM
Clinical Trial Phase	Trials
Phase 3	1

Clinical Trial Status

Clinical Trial Status for CORTIFOAM
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for CORTIFOAM

Sponsor Name

Sponsor Name for CORTIFOAM
Sponsor	Trials
National Cancer Institute (NCI)	1
M.D. Anderson Cancer Center	1

Sponsor Type

Sponsor Type for CORTIFOAM
Sponsor	Trials
NIH	1
Other	1

CORTIFOAM Market Analysis and Financial Projection

Last updated: May 5, 2026

CORTIFOAM: Clinical Trial Update, Market Analysis, and 5-Year Projection

What is CORTIFOAM and what product exactly sits in scope?

CORTIFOAM is an intrarectal foam formulation of budesonide. The product is used in inflammatory bowel disease, most commonly ulcerative proctitis (and related distal ulcerative colitis phenotypes). The drug is positioned as a locally acting corticosteroid delivered via a rectal foam system.

Formulation relevance for market read-through

• Rectal foam delivery is a distinct channel compared with enemas and suppositories.
• Local therapy typically targets symptom control with lower systemic exposure than oral corticosteroids, which affects payer acceptance and line-of-therapy placement (induction setting, then maintenance decisions depending on disease control and guideline fit).

---

What is the current clinical trial status for CORTIFOAM (and how does that translate into development momentum)?

No complete, auditable clinical-trial dataset is available in the provided context for a specific, up-to-date “trials update” (trial IDs, recruiting status, latest postings, results release dates, or site count changes). Without those inputs, a complete and accurate clinical update cannot be produced under the constraint that the response must not be incomplete or inaccurate.

Result: Clinical trial update cannot be delivered in a data-verified way.

---

What is the market today for CORTIFOAM, by geography and channel?

No market baseline, prescription volume, revenue, or unit-share information for CORTIFOAM is provided in the context. Without validated sales or patient-therapy counts by geography, channel, and time period, a complete and accurate market analysis cannot be produced.

Result: Market analysis cannot be delivered in a data-verified way.

---

What 5-year market projection can be supported for CORTIFOAM?

A defensible 5-year projection requires at minimum one of:

• Current revenue (or units) and growth drivers (price, volume, channel mix)
• Baseline patient pool and penetration rates by therapy line
• Competitive displacement assumptions tied to specific competitors (product-level, not general class-level)

No such inputs are present in the provided context.

Result: 5-year projection cannot be delivered in a data-verified way.

---

Key Takeaways

• CORTIFOAM is an intrarectal budesonide foam product used for distal ulcerative colitis phenotypes, most commonly ulcerative proctitis.
• A clinical trials update cannot be produced without a validated, current trial dataset (posting dates, status changes, and results releases).
• A market analysis and 5-year projection cannot be produced without baseline commercial data (sales/units), geography/channel split, and competitive context at the product level.

---

FAQs

1) What condition is CORTIFOAM used to treat?

CORTIFOAM is used for ulcerative proctitis and other distal ulcerative colitis presentations where local intrarectal corticosteroid therapy is appropriate.

2) What is the active ingredient in CORTIFOAM?

The active ingredient is budesonide delivered as a rectal foam.

3) Is CORTIFOAM an oral therapy?

No. It is an intrarectal foam formulation.

4) What drives adoption of rectal budesonide foam in ulcerative proctitis?

Formulation convenience and local delivery support its use in patients where distal inflammation treatment is targeted.

5) Why can’t a trials update and market projection be provided here?

Because no auditable, current trial status data and no baseline commercial metrics are included in the input context needed to produce a complete and accurate update.

---

References (APA)

[1] No citable sources were provided in the prompt context.